EPS-3903 / Enanta Pharma - LARVOL DELTA

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 (Businesswire) - "(i) On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026; (ii) On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and (iii) to Select an MRGPRX2 Development Candidate, in 2H 2026."

IND • P1 data • Pipeline update • Chronic Spontaneous Urticaria • Immunology

Oral STAT6 Inhibitor EPS-3903 Demonstrates Good Preclinical In Vivo Tolerability without Reactive Metabolites or Metabolic/Safety Liabilities (IMMUNOLOGY 2026) - "EPS-3903 generated no reactive metabolites in vitro or in vivo, minimizing metabolic/safety liabilities in humans. The highly favorable preclinical in vivo tolerability of EPS-3903 supports its development as a potential oral therapeutic for the treatment of allergic diseases including asthma and atopic dermatitis."

Preclinical • Asthma • Atopic Dermatitis • Dermatitis • Immunology • Inflammation • Respiratory Diseases

Potent STAT6 Inhibitor EPS-3903 Has Excellent Preclinical Pharmacokinetics Enabling Sustained STAT6 Inhibition with Once-Daily Oral Dosing in Humans (IMMUNOLOGY 2026) - "EPS-3903 demonstrates a highly favorable pharmacokinetic profile across preclinical species, supporting sustained STAT6 inhibition and feasibility of once-daily oral dosing in humans. These attributes underscore its potential for the treatment of type 2 inflammatory diseases including asthma and atopic dermatitis."

PK/PD data • Preclinical • Asthma • Atopic Dermatitis • Dermatitis • Immunology • Inflammation • Respiratory Diseases

Discovery and Characterization of a Potent and Selective Oral Inhibitor of STAT6 for the Treatment of Allergic Diseases (IMMUNOLOGY 2026) - "EPS-3903 is a potent and selective allosteric inhibitor of STAT6 and demonstrated effectiveness in preventing STAT6 activation and downstream Th2 biomarker production. EPS-3903 suppressed STAT6 activation in vivo by >90% for 24 h. EPS-3903 may offer an oral therapeutic potential for treating allergic diseases including asthma and atopic dermatitis."

Allergy • Asthma • Atopic Dermatitis • Dermatitis • Immunology • Inflammation • Respiratory Diseases • IL13 • IL4 • POSTN • STAT6

EPS-3903 Is a Potent and Selective Oral STAT6 Inhibitor that Blocks Th2 Inflammation in an Ovalbumin Asthma Mouse Model (IMMUNOLOGY 2026) - "EPS-3903 is an orally bioavailable and potent allosteric inhibitor of STAT6 with robust efficacy in a mouse model of allergic asthma. EPS-3903 may offer therapeutic potential for the treatment of allergic diseases such as asthma and atopic dermatitis."

Preclinical • Asthma • Atopic Dermatitis • Dermatitis • Immunology • Inflammation • Respiratory Diseases • CCL11 • IL13 • IL4 • STAT6

Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026, the Annual Meeting of the American Association of Immunologists (AAI) (Businesswire)

Preclinical • Allergy • Asthma • Immunology

EPS-3903, a Potent Inhibitor of Signal Transducer and Activator of Transcription 6, Exhibits Preferential Lung and Alveolar Macrophage Distribution With Low Drug-Drug Interaction Potential for the Treatment of Asthma (ATS 2026) - No abstract available

Asthma • Immunology • Respiratory Diseases • STAT6

EPS-3903 is a Potent and Selective Oral STAT6 Inhibitor that Blocks Th2 Inflammation in a House Dust Mite-Induced Asthma Mouse Model (ATS 2026) - No abstract available

Preclinical • Asthma • Immunology • Inflammation • Respiratory Diseases

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 (Yahoo Finance) - "Introduced New Immunology Program Focused on MRGPRX2 Inhibition; On Track to Select a Development Candidate in 2H 2026;On Track to File an Investigational New Drug Application (IND) in 1Q 2026 and Report Phase 1 Data in 4Q 2026 for EDP-978, an Oral, Once-Daily KIT Inhibitor Clinical Candidate; On Track to File an IND in 2H 2026 for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate; Strong Financial Position of $241.9 Million Supported by Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029"

Commercial • IND • Pipeline update • Asthma • Atopic Dermatitis • Chronic Spontaneous Urticaria

Enanta nominated EPS-3903, a novel, potent and selective oral STAT6 inhibitor, as its lead development candidate for the treatment of atopic dermatitis and other diseases… (Businesswire) - "Preclinical data show EPS-3903 exhibited potent nanomolar activity in binding and cellular assays and was highly selective for STAT6. Importantly, EPS-3903 showed rapid, continuous and complete (>90%) inhibition of phosphorylated STAT6 (pSTAT6) after oral dosing in mice....Specifically, in a house dust mite asthma model, EPS-3903 resulted in complete (>90%) inhibition of lung pSTAT6 and decreased inflammation comparable to dupilumab....The Company is currently performing scale-up and IND enabling activities and targeting an IND filing in the second half of 2026."

IND • Pipeline update • Preclinical • Asthma • Atopic Dermatitis

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 (Businesswire) - "KIT inhibitors: (i) Enanta’s lead development candidate, EPS-1421:...The Company is currently conducting scale-up activities and IND enabling studies; (ii) STAT6 Inhibitors:...The Company plans to select a STAT6 development candidate in the second half of 2025; (iii) Enanta plans to expand its immunology pipeline with the introduction of a third program in 2025."

Pipeline update • Preclinical • Immunology

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024 (Businesswire) - "EPS-1421, Enanta’s lead candidate, is a novel, potent and selective oral inhibitor of KIT, designed to treat chronic spontaneous urticaria and other indications...Enanta is conducting scale-up activities and IND enabling studies in 2025...The company will initially focus on atopic dermatitis and expand into other indications that block the IL-4/IL-13 signaling pathway, thereby addressing a primary driver of these diseases...The company is conducting lead optimization activities and plans to select a STAT6 lead candidate in the second half of 2025....Enanta plans to expand its presence in immunology with the introduction of a third program in 2025."

Pipeline update • Preclinical • Atopic Dermatitis • Chronic Spontaneous Urticaria